

The convergence of robotics, machine intelligence and life sciences has enabled breakthrough advances that should profoundly transform the healthcare industry, offering a potential opportunity to investors over the next decade. The HTEC ETF provides global exposure to companies leading the healthcare technology revolution, across diagnostics, robotics, genomics, precision and regenerative medicine, lab automation, instruments, data analytics and telehealth.

Why HTEC ?

1. INDUSTRY EXPERTS ⁽¹⁾ specializing in robotics, artificial intelligence (AI), and healthcare technologies whose mission is to define and identify the universe of healthcare innovation for investors.

2. GLOBAL EXPOSURE to the value chain of healthcare technologies and life sciences companies, across 9 subsectors positioned for market growth.

3. MULTI-CAP fund providing diversified access to large-, mid- and small-cap companies with minimal overlap with most broad market indices.

KEY FACTS

Fund Launch Date	06/24/2019
Assets Under Management (\$ million)	\$236.81
Benchmark Index	ROBO GLOBAL [®] HEALTHCARE TECHNOLOGY AND INNOVATION INDEX
Number of Equity Holdings	84
Expense Ratio (Gross / Net*)	0.80% / 0.68%
Rebalance Frequency	Quarterly
Ticker	HTEC
CUSIP	301505723
Exchange	NYSE Arca

* The advisor has contractually agreed to waive fees through August 31, 2021

FUND CHARACTERISTICS

Beta vs. S&P 500	0.85
Beta vs. ACWI	1.05
Standard Deviation	26.46%
Sharpe Ratio	1.48
Price to Earnings	73.14
Price to Book	7.20

PERFORMANCE

	QTD	YTD	1 YR	SI
HTEC @ NAV	9.57%	10.02%	56.51%	40.24%
HTEC @ Mkt Price	9.75%	10.18%	57.37%	40.37%
HTECTR Index	9.76%	10.35%	57.56%	41.26%

The performance data quoted is as of June 30, 2021 and represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original costs. Current performance may be higher or lower than the performance quoted. For performance data current to the most recent month end, please call 1-855-456-7626 or visit www.roboglobal.etfs.com. Periods greater than 1 year have been annualized. (SI) since inception


GROWTH OF \$10,000 SINCE INCEPTION



The above chart reflects a hypothetical \$10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses and fees were deducted.

Beginning September 1, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn't available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates current NAV per share. Prior to September 1, 2020, market price returns were based on the midpoint between the bid and ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times.

ROBO GLOBAL® INDUSTRY CLASSIFICATION




TOP HOLDINGS


EDITAS MEDICINE INC	2.29%
VERACYTE INC	1.65%
NATERA INC	1.59%
GLAUKOS	1.57%
FULGENT GENETICS INC	1.57%
VOCERA COMMUNICATIONS INC	1.56%
AXOGEN INC	1.55%
ILLUMINA INC	1.54%
TABULA RASA HEALTHCARE INC	1.54%
THERMO FISHER SCIENTIFIC INC	1.53%

Subject to change. Current and future holdings subject to risk. **16.40%**

MARKET CAPITALIZATION BREAKDOWN



GEOGRAPHIC BREAKDOWN



GLOSSARY

Industry Experts ⁽¹⁾ Through expertise of its leadership team and strategic advisors, including 7 PhDs in the fields of engineering and robotics, ROBO Global® searches worldwide to find cutting-edge companies deploying robotic, automation, artificial intelligence, and healthcare technology solutions to industries and people. By defining the ecosystem, they are able to track the global growth of the industry.

S&P 500 is an equities index generally considered to be a benchmark for the US equities market. It is comprised of the 500 largest companies having common stock listed on the NYSE or NASDAQ.

ACWI The MSCI All Country World Index is a global index generally considered to be a broad measure of equity-market performance throughout the world.

Beta is a measure of the volatility of a portfolio in comparison to the market as a whole.

Standard Deviation is a measure used to quantify the amount of variation in a set of data values.

Sharpe Ratio is a risk-adjusted measure that calculates excess performance with respect to the risk-free rate, per unit of volatility over time.

Beta, Standard Deviation and Sharpe ratio are calculated on the last 36 months.

RISK DISCLOSURE AND IMPORTANT INFORMATION

Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and additional information can be found on the Fund's full or summary prospectus, which may be obtained at www.roboglobal.etfs.com. Read the prospectus carefully before investing.

Exchange Traded Concepts, LLC serves as the investment advisor to the Fund. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.

Investing involves risk, including the possible loss of principal. Narrowly focused investments and investments in smaller companies typically exhibit higher volatility. International investments may also involve risk from unfavorable fluctuations in currency values, differences in generally accepted accounting principles, and from economic or political instability. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Diversification may not protect against market risk. Indices are unmanaged. One cannot invest directly in an index. There is no guarantee the fund will achieve its stated objective.

The Fund invests primarily in the equity securities of Medical Technology Companies and, as such, is particularly sensitive to risks to those types of companies. These risks include, but are not limited to, small or limited markets for such securities, changes in business cycles, world economic growth, technological progress, rapid obsolescence, and government regulation.